Skip to main content

Table 1 Distribution of patients within each treatment arm by simplified MIPI risk category [13,14]

From: Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

Patients Low risk Intermediate risk High risk
n (%) n (%) n (%)
All patients (N = 162) 51 (31) 63 (39) 48 (30)
Temsirolimus 175/75 mg (n = 54) 14 (26) 24 (44) 16 (30)
Temsirolimus 175/25 mg (n = 54) 15 (28) 18 (33) 21 (39)
INV therapy (n = 54) 22 (41) 21 (39) 11 (20)
  1. MIPI = Mantle Cell Lymphoma International Prognostic Index; INV = Investigator’s choice.